BioNTech and Ryvu Therapeutics enter partnership

Research collaboration for several small molecule immunotherapy programs

02-Dec-2022 - BioNTech SE and Ryvu Therapeutics S.A., a clinical-stage company developing oncology therapeutics announced that the companies have entered into a multi-target research collaboration for several small molecule immunotherapy programs as well as an exclusive license agreement for Ryvu’s STING ...

€12M Series A Financing to Develop Novel Immuno-Virotherapies Against Cancer

17-Oct-2019 - Abalos Therapeutics announced a EUR 12 million Series A financing round establishing its operations and leadership. The Company’s objective is to develop new immuno-oncology therapeutics based on a specific arenavirus strain that preferentially infects and proliferates in cancer cells generating ...

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

CureVac to receive an upfront payment of $50 million and an equity investment of €45 million

19-Oct-2017 - Eli Lilly and Company and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac’s proprietary RNActive® technology. The companies will use messenger RNA (mRNA) technology ...

Merck Licenses Four Oncology Research and Development Programs from Vertex

Vertex receives upfront payment of $230 million plus royalties on future sales

12-Jan-2017 - Merck announced that it has entered into a licensing agreement with Vertex Pharmaceuticals Inc. for the worldwide development and commercialization of four promising research and development programs that represent novel approaches to the treatment of cancer.“With this strategic deal we ...

Merck Serono and Intrexon Announce Agreement for the Development and Commercialization of CAR-T Therapy

02-Apr-2015 - Merck Serono and Intrexon Corporation announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances Merck Serono’s comprehensive, science-driven strategy to develop ...

Merck on Track with Pharma Strategy

Pipeline Progress Announced

22-Sep-2014 - Merck announced that its biopharmaceutical division Merck Serono is well on track with the implementation of the Group’s “Fit for 2018” transformation and growth program. This is reflected by efficiency gains and the successful execution of growth initiatives as well as progress in the pipeline, ...

Merck Serono and MorphoSys Enter Strategic Immuno-Oncology Collaboration

13-Jun-2014 - Merck and MorphoSys AG announced that they have signed an agreement to discover and develop therapeutic antibodies against undisclosed immune checkpoints. Under the terms of the agreement, MorphoSys and Merck Serono will join forces to develop therapies that modulate the immune system’s natural ...